Why the warning matters

The pancreas helps with digestion and controls blood glucose. Acute pancreatitis means sudden inflammation of the pancreas. Most tummy discomfort has another cause. Pancreatitis can become severe, and no checklist at home can safely rule the condition out.

In January 2026 the MHRA strengthened its warnings for the whole class of medicines, highlighting reports of severe, necrotising and fatal cases. Severe pancreatitis remains uncommon. The warning exists because delay causes serious harm, even with a rare event.

The pattern to watch for

The main warning sign is severe pain that persists. A brief, mild cramp is different. The pain may sit in the upper abdomen and spread to your back, with nausea or vomiting. Do not wait for every textbook symptom or for pain to appear at a set time after an injection.

Use emergency services for severe illness, collapse, breathing difficulty or other emergency signs. When you are assessed, say you take semaglutide and give the exact product, dose and date of your last injection. Bring a medicine list or the packaging if you have one to hand, but do not delay care to find it.

What assessment involves

Clinicians assess your pain, examine you and run blood tests, sometimes with a scan. A raised pancreatic enzyme alone does not confirm pancreatitis. Someone who looks well may still need investigation. An online test with no one to interpret the result cannot replace an assessment of your symptoms.

Other conditions, including gallstones, cause similar pain or trigger pancreatitis. The team needs to know about past episodes, alcohol, gallbladder disease and your other medicines. These are clinical questions. Nobody is looking to blame you.

Reading risk figures

Spontaneous Yellow Card reports are signals for safety monitoring. You cannot work out your own chance of pancreatitis from them. Some events go unreported, some reports are incomplete, and the number of packs dispensed differs from the number of people treated.

Trial rates describe selected groups over a set period. They may not predict risk well for someone with a previous episode. Tell your prescriber about any history of pancreatitis before you start Wegovy. Evidence in that group is limited and caution is needed.

After an episode

If pancreatitis is confirmed, UK product information says semaglutide should not be restarted. The clinicians treating you decide on any alternative medicine. Switching to another GLP-1 product on your own is not a safe workaround.

After urgent care, make sure your prescribing service and GP get the outcome so they can update your records and stop repeat supplies. Patients and professionals can report a suspected side effect to the MHRA Yellow Card scheme. Reporting helps safety monitoring. Get medical care first and report afterwards.

Sources

Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.

  1. Wegovy FlexTouch UK prescribing information medicines.org.uk
  2. MHRA: strengthened pancreatitis warnings gov.uk
  3. NHS: acute pancreatitis nhs.uk

Spotted something out of date? Report a mistake.